Tarka vs. Hyzaar in Patients With Metabolic Syndrome (STAR)
Information source: Abbott
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension; Metabolic Syndrome
Intervention: trandolapril/verapamil (Drug); (Hyzaar) losartan/hydrochlorothiazide (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Abbott Official(s) and/or principal investigator(s):
Global Medical Information, Study Director, Affiliation: Abbott
Summary
The primary objective of this study is to determine whether impaired glucose tolerance is
improved to a greater degree by Tarka than Hyzaar in subjects with metabolic syndrome
Clinical Details
Official title: A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Oral Glucose Tolerance
Secondary outcome: Changes in blood pressure (BP), pulse rate and BP control. HbA1c, insulin sensitivity, insulin release, albuminuria, lipid profile, AMBP, clinical safety labs and adverse events.
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Metabolic syndrome
- Fasting blood glucose between 100 mg/dL and 125 mg/dL
- Hypertension
- One additional criteria, Exclusion 1
Exclusion Criteria:
- Subject has a current diagnosis of Type 1 or Type 2 diabetes mellitus.
- Subject has a hypersensitivity to ACE inhibitor, ARB, CCB, clonidine, methyldopa,
hydralazine, or thiazide diuretic medication.
Locations and Contacts
Additional Information
Starting date: March 2004
Last updated: July 11, 2008
|
